Skip to content
Bamboo Works
Search
Register / Sign in
MSCI China | MSCI China Small-Cap | Hang Seng Index | Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Premium Content
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Premium Content
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

PD-1 antibody

Lepu touts itself as the only biotech company in China working on all three very promising fronts, with PD-1 products in the new drug application (NDA) stage, multiple “smart missile” antibody-drug conjugate (ADC) products in clinical trials, and OV products under development.

FAST NEWS: Lepu Biopharma to raise $32 million in share sale

The Latest: Innovative drug maker Lepu Biopharma Co. Ltd. (2157.HK) announced on Friday it will place up to 51.17 million shares, or about 2.99% of its overall issued share capital, for…
May 17, 2024
2157.HK

Will Junshi Bio’s loss-making headaches ease with landmark U.S. drug approval?

The FDA has given the nod to the Chinese company’s PD-1 drug, but most of the benefits will go to a third-party licensee Key Takeaways: Junshi Bio will receive milestone…
November 9, 2023
1877.HK 688180.SHG

Lepu Biopharma gets taste of spring with first revenues

The ADC-focused drug company logged its first-ever sales late last year, kicking of the next phase of its development Key Takeaways: Lepu Biopharma began to sell its first product last…
March 23, 2023
2157.HK

Recent Articles

Lepu touts itself as the only biotech company in China working on all three very promising fronts, with PD-1 products in the new drug application (NDA) stage, multiple “smart missile” antibody-drug conjugate (ADC) products in clinical trials, and OV products under development.
May 17, 2024

FAST NEWS: Lepu Biopharma to raise $32 million in share sale

2157.HK
November 9, 2023

Will Junshi Bio’s loss-making headaches ease with landmark U.S. drug approval?

1877.HK 688180.SHG
March 23, 2023

Lepu Biopharma gets taste of spring with first revenues

2157.HK

RELATED ARTICLES

  1. Genfleet bio
    January 9, 2025
    Cancer drug maker Genfleet joins Hong Kong IPO influx
  2. March 20, 2025
    A blockbuster cancer drug? TYK’s claims go under the microscope
    2410.HK
  3. February 20, 2025
    NEWS WRAP: Surging Xtalpi seizes on tech rally to raise $267 million
    2228.HK
  4. December 2, 2024
    Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
    1952.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Premium Content
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2024 Bamboo Works. All rights reserved.